Sinovac vaccines induced neutralizing antibody responses to live novel coronavirus in adults aged 60 and above, according to the results from the Phase-I and Phase-II clinical trials. All adverse reactions observed among elderly groups were of mild or moderate severity. Graphic: Feng Qingyin/GT